Apart from the predominant role of Aβ and tau pathology in AD, neuroinflammation has emerged as a driver and an accelerator of AD pathology [4–6], and therefore provides a broad window of opportunity (from early to late-stage AD) for therapeutic intervention. The gene discussed is MAPT; the disease is Alzheimer disease.